Your browser doesn't support javascript.
loading
Epstein Barr virus-directed T-cell therapy for refractory EBV-PTLD in a toddler post Orthotopic heart transplantation.
Work, Emily; Gupta, Dipankar; Slayton, William B; Rees, John; Coppola, John-Anthony; Seifert, Robert; Bleiweis, Mark S; Jacobs, Jeffrey P; Peek, Giles; Philip, Joseph; Brock, Alan; Rivera, Jose Hernandez; Sullivan, Kevin; Narasimhulu, Sukumar Suguna.
Afiliación
  • Work E; University of Florida, Gainesville, Florida, USA.
  • Gupta D; Congenital Heart Center, University of Florida, Gainesville, Florida, USA.
  • Slayton WB; Division of Hematology and Oncology, University of Florida, Gainesville, Florida, USA.
  • Rees J; Department of Radiology, University of Florida, Gainesville, Florida, USA.
  • Coppola JA; Congenital Heart Center, University of Florida, Gainesville, Florida, USA.
  • Seifert R; Department of Pathology, University of Florida, Gainesville, Florida, USA.
  • Bleiweis MS; Congenital Heart Center, University of Florida, Gainesville, Florida, USA.
  • Jacobs JP; Congenital Heart Center, University of Florida, Gainesville, Florida, USA.
  • Peek G; Congenital Heart Center, University of Florida, Gainesville, Florida, USA.
  • Philip J; Congenital Heart Center, University of Florida, Gainesville, Florida, USA.
  • Brock A; Congenital Heart Center, University of Florida, Gainesville, Florida, USA.
  • Rivera JH; Congenital Heart Center, University of Florida, Gainesville, Florida, USA.
  • Sullivan K; Congenital Heart Center, University of Florida, Gainesville, Florida, USA.
  • Narasimhulu SS; Congenital Heart Center, University of Florida, Gainesville, Florida, USA.
Pediatr Transplant ; 28(2): e14707, 2024 Mar.
Article en En | MEDLINE | ID: mdl-38419558
ABSTRACT
Epstein-Barr Virus (EBV) is a ubiquitous herpes type virus that is associated with post-transplant lymphoproliferative disorder (PTLD). Usual management includes reduction or cessation of immunosuppression and in some cases chemotherapy including rituximab. However, limited therapies are available if PTLD is refractory to rituximab. Several clinical trials have investigated the use of EBV-directed T cells in rituximab-refractory patients; however, data regarding response is scarce and inconclusive. Herein, we describe a patient with EBV-PTLD refractory to rituximab after orthotopic heart transplantation (OHT) requiring EBV-directed T-cell therapy. This article aims to highlight the unique and aggressive clinical presentation and progression of PTLD with utilization of EBV-directed T-cell therapy for management and associated pitfalls.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante de Corazón / Trasplante de Células Madre Hematopoyéticas / Infecciones por Virus de Epstein-Barr / Trastornos Linfoproliferativos Límite: Child, preschool / Humans Idioma: En Revista: Pediatr Transplant Asunto de la revista: PEDIATRIA / TRANSPLANTE Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante de Corazón / Trasplante de Células Madre Hematopoyéticas / Infecciones por Virus de Epstein-Barr / Trastornos Linfoproliferativos Límite: Child, preschool / Humans Idioma: En Revista: Pediatr Transplant Asunto de la revista: PEDIATRIA / TRANSPLANTE Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos